Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NUVB vs RCUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NUVB Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

NUVB Overall Winner 6-Pillar Tally: NUVB 4 – 1 RCUS (1 Tie) Matrix Metrics: NUVB 5 – 3 RCUS

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas RCUS carries 48.9/100 (HOLD) at $15.62 (N/M Forward P/E, -475.0% operating margin).

  • Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NUVB vs RCUS
NUVB NYSE Head-to-Head Winner
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87
RCUS NYSE
Arcus Biosciences, Inc.
Pharmaceutical Preparations
$15.62
-1.01% 1D
Market Cap $2.3B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.39β · 54% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 44.0 Fund 56.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 29
RSI-14: 28.6 · SMA20: $17.76 · SMA50: $21.47

6-Pillar Scorecard Institutional Category Breakdown (NUVB 4 – 1 RCUS)

Columns: Metric · NUVB · RCUS
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x 22.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) +242.6% -65.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $202M $100M
Market Cap $1.3B $2.3B
3. Profitability & Quality NUVB
Gross Margin 85.8% N/A
Operating Margin -61.2% -475.0%
Net Profit Margin -67.4% 0.0%
Return on Equity (ROE) -49.1% -114.1%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$108M -$466M
Cash Flow Margin -53.6% N/A
Net Cash / Leverage $146M Net Debt (1.32x D/E) $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCUS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 65.2% (26th %ile) 98.2% (11th %ile)
Put/Call OI Skew 0.24x (Call-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NUVB (5) vs RCUS (3)
Institutional Metric NUVB RCUS Criterion Row Edge
Market Capitalization
Scale
$1.3B $2.3B Larger Scale RCUS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+242.6% -65.4% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-61.2% -475.0% Higher Margin NUVB
Net Profit Margin
Profitability
-67.4% 0.0% Higher Margin RCUS
Return on Equity (ROE)
Capital Efficiency
-49.1% -114.1% Higher ROE NUVB
52-Week Range Position
Momentum
2% ($4–$10) 0% ($16–$32) Stronger Trend NUVB
Beta / 30D Volatility
Risk Regime
1.52β · 55% Vol 1.39β · 54% Vol Lower Realized Risk RCUS
Unified Institutional Score
Composite Signal
61.0 / 100 (BUY) 48.9 / 100 (HOLD) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$202M $100M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · 22.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($146M Net Debt (1.32x D/E)) -$466M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NUVB +0.17 pp
NUVB: -19.15% · RCUS: -19.32%
3M Horizon NUVB +4.35 pp
NUVB: -43.79% · RCUS: -48.14%
6M Horizon NUVB +13.84 pp
NUVB: -19.49% · RCUS: -33.33%
1Y Horizon RCUS +24.1 pp
NUVB: -46.85% · RCUS: -22.75%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NUVB Revenue RCUS Revenue NUVB Op. Margin RCUS Op. Margin Margin Leader
FY2018 N/A $10M N/A -656.8% RCUS
FY2019 N/A $10M N/A -591.4% RCUS
FY2020 N/A $80M N/A -159.0% RCUS
FY2021 N/A $380M N/A 14.1% RCUS
FY2022 N/A $40M N/A -736.8% RCUS
FY2023 N/A $40M N/A -918.9% RCUS
FY2024 $10M $50M -7527.3% -647.1% RCUS
FY2025 $60M $30M -338.7% -1169.7% NUVB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCUS BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 98.2%
IV Percentile 11th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact RCUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCUS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3B market capitalization and -475.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NUVB vs RCUS Key Questions & Quantitative Answers

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas RCUS carries 48.9/100 (HOLD) at $15.62 (N/M Forward P/E, -475.0% operating margin). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with RCUS at -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NUVB cumulative revenue shifted +500.0% while RCUS shifted +200.0%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCUS.

NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 22.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus RCUS (-114.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, RCUS carries 98.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.